Ratings PharmaBlock Sciences (Nanjing), Inc.

Equities

300725

CNE1000035K5

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 06/06/2024 BST			5-day change	1st Jan Change
29.09 ^CNY	-1.39%		-7.15%	-25.92%

06-07	PharmaBlock Sciences, Inc. Announces Dividend on Share A for the Year 2023, Payable on June 14, 2024	CI
05-20	PharmaBlock Sciences, Inc. Approves Cash Dividend for the Year 2023	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 63% by 2026.
The earnings growth currently anticipated by analysts for the coming years is particularly strong.
The group's high margin levels account for strong profits.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
PHARMABLOCK SCIENCES (NANJING), INC.	-25.92%	798M	-
ELI LILLY AND COMPANY	+45.82%	765B	C+
NOVO NORDISK A/S	+40.95%	632B	B
JOHNSON & JOHNSON	-6.16%	354B	C+
MERCK & CO., INC.	+19.86%	331B	B-
ABBVIE INC.	+9.32%	299B	C+
ASTRAZENECA PLC	+18.45%	248B	B+
ROCHE HOLDING AG	-0.78%	219B	A+
NOVARTIS AG	+11.88%	216B	B-
AMGEN INC.	+5.90%	164B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes